🔥The 9th Round of Easy Loan, Earn $40 Reward is in progress❗️ ⏰ Promotion Period: January 15th - Feburary 15th, 2025 👉 Register now and check more details at gate.io/campaigns/358

Fitness assessment in acute myeloid leukemia: recommendations from an expert panel on behalf of the European LeukemiaNet ashpublications.org/bloodadvances/… Age only should NOT be the criteria of fitness for intensity of therapy in AML. We should also consider 👇🏽 Co-morbidities

An international study led by CU Cancer Center has uncovered why a widely used treatment for acute myeloid #leukemia doesn’t work for everyone. The findings could help doctors better match patients with the therapies most likely to work for them. 💡 news.cuanschutz.edu/news-stories/n…

Multimodal spatial proteomic profiling in acute myeloid leukemia nature.com/articles/s4169…

Excited to share with all our latest work on the use of single cell tools in following IDH mutant AML patients during their treatment! Out today Cell Stem Cell !! An amazing collaboration with AK Eisfeld & Elli Papaemmanuil, PhD & Dan Landau !!! Driven by the impressive Maria Sirenko

Online First: Genetic and Phenotypic correlates of clinical outcomes with Venetoclax in Acute Myeloid Leukemia: The GEN-PHEN-VEN study doi.org/10.1158/2643-3…

Just had a chance to read through (briefly- will need to read again) and this is very cool! Congrats to all involved. 👏👏👏

Check out this study led by Anand Patel Toyosi Odenike Michael Drazer investigating the LSD1 inhibitor iadademstat combined with ASTX727 in accelerated/blast-phase MPNs! clinicaltrials.gov/study/NCT06661…

Are you ready for it? VEN-HMA for younger patients with AML >>> Venetoclax and decitabine vs intensive chemotherapy as induction for young patients with newly diagnosed AML doi.org/10.1182/blood.… #leusm #AML

Thanks for the awesome cover art Blood Cancer Discovery!!

🧵1/ T cells have deservedly been in the🔦for #cancer #immunotherapy, but other engineered cell therapies are now📈. What mediates NK cell exhaustion remains an important unanswered❓. 📄Link: nature.com/articles/s4158… I’m so thrilled🥳to share our work out now🚨nature

As presented by Joshua Zeidner MD. AZA+VEN+REV in ND-AML 👇

Could pts with prior VEN therapy still benefit from adding VEN to chemo? MDS/AML pts with prior HMA+VEN tx had a 39% CR/CRi rate and 33% were bridged to allo-HSCT with chemo+VEN. This small but highly pretreated cohort suggests this approach could be useful in a subset of pts.

Outcomes of Frontline Triplet Regimens With a Hypomethylating Agent, Venetoclax, and Isocitrate Dehydrogenase Inhibitor for Intensive Chemotherapy–Ineligible Patients With Isocitrate Dehydrogenase–Mutated AML. Co-authored by Jen Marvin-Peek, MD. Full article. brnw.ch/21wTx9F

It finally here 🥳 brnw.ch/21wTSQI If you’re like us & your (professional) 🌍 revolves around myeloid neoplasms we hope you’ll enjoy reading this paper. So many colleagues & collaborators to 🙏🏻 for helping us get this to 🏁 … tweetorial & acknowledgements coming soon